Kati Medicine completed over 70 million yuan of a + round financing and accelerated the application of pilot product ind and pipeline development
Recently, Nanjing Kati Medical Technology Co., Ltd., a domestic cutting-edge enterprise of car-t cell therapy for solid tumors, completed a round of a + financing with a total amount of more than 70 million yuan. This round of financing is jointly completed by Nanjing Chengyi investment, Qiandao group, Suzhou Guanya investment and Haihui investment. This round of financing will be mainly used to promote the application of the leading product ind of Kati medicine. Founded in 2017 and headquartered in Nanjing Biological Medicine Valley in Nanjing National Jiangbei new area, Kati medicine is a key enterprise in the field of gene and life health and a national high-tech innovation enterprise in Jiangbei new area. Kati medicine focuses on the development of new drugs for car-t cells in solid tumors.
This text is a result of machine translation.
Briefing Jun 28, 2022 09:56 AM
· Healthcare
And platinum medicine b7h4x4-1bb bispecific antibody were approved by FDA for new drug research
Briefing Jun 28, 2022 09:54 AM
· Healthcare
Fosun pharma and Amgen have reached cooperation to accelerate the commercialization of two innovative drugs in China
In-depth
Briefing Jun 28, 2022 09:50 AM
· Healthcare
It is expected to achieve functional cure of chronic hepatitis B! GSK antisense therapy phase IIB positive clinical results
Briefing Jun 28, 2022 09:37 AM
· Healthcare
Aibo biology: cooperate with Jiahe biology to jointly develop tumor mRNA drugs
Apr 22, 2021 03:11 PM
Research
Technology, Healthcare, Consumer StaplesWIA2020 | Rising Tech Stars 2020: Global & China's 100
Dec 09, 2020 09:57 AM
Dec 09, 2020 09:39 AM
Research
Technology, Real Estate, IndustrialsTech for Global, Globalization Footprints of the Established and the New
May 29, 2020 08:30 PM
Briefing Jun 24, 2022 11:15 AM
· Healthcare
F-star to be acquired by China biopharmaceutical with USD 161million
Briefing Jun 24, 2022 11:07 AM
· Healthcare
"Delisting warning" of Whitson pharmaceuticals on the New York Stock Exchange
Briefing Jun 24, 2022 10:46 AM
· Healthcare
East China medicine "liraglutide" goes to sea
Healthcare
Biotech Astrabio Nets Nearly CNY 100 Mn in Series A financing Round
Astrabio, specializing in the Single Molecule Counting technology, will continue to promote the revolution of the next-generation immunoassay technology by further accelerating the R&D and clinical translation of new biomarkers with the fresh proceeds.
Updated 8 hours ago
Briefing Jun 23, 2022 06:25 PM
· Healthcare
Nearly half of the equity of two subsidiaries of Tongrentang was transferred to Tongrentang medical care
Briefing Jun 23, 2022 06:24 PM
· Healthcare
Baiyunshan: suspension of the spin off of Guangzhou Pharmaceutical for overseas listing
Briefing Jun 23, 2022 10:36 AM
· Healthcare
Germany Merck "cetuximab" new indications for head and neck squamous cell carcinoma approved in China
Healthcare
Biotech Firm ImmuneOnco Submitted Listing Application on the Main Board of HKEX
ImmuneOnco, focusing on developing new-generation tumor immunotherapeutic, will further accelerate the development of other promising drug candidates targeting checkpoints of innate and adaptive immunity.
Jun 28, 2022 10:58 PM
Briefing Jun 23, 2022 10:27 AM
· Healthcare
Yanye new crown drug 3CL protein inhibitor has been suspended approval
Briefing Jun 23, 2022 10:24 AM
· Healthcare
Sanofi Greater China will be headed by Shi Wang, and Henting he will become the global head of the digital business unit
Briefing Jun 23, 2022 10:22 AM
· Healthcare
Acadia Alzheimer's drug SNDA application rejected by FDA advisory committee
Briefing Jun 23, 2022 10:20 AM
· Healthcare
Huashen Zhiyao completed nearly 500million yuan of a-round financing and went deep into AI new drug development
See more
Read next
In-depth
In-depth
In-depth
Technology
A Closer Look at China’s Cloud Service Market, Guessing Who Will Succeed? [1/2]
Jun 27, 2022 05:09 PM
In-depth
Healthcare
Exclusive Interview with Xu Qian, Managing Partner of Redhill Capital
Jun 27, 2022 12:24 PM
EqualOcean is an information service provider and investment research company that aims to become a global platform for industrial innovation. Founded in February 2014 and headquartered in Beijing, with a client network covering over 50 countries, the firm provides comprehensive professional services, including industry research, investment analysis, innovation consulting, data products, corporate branding and international strategy.